Physician profile

Mark Bradford

Olympia, WA

NPI 1548335938

$3,629.68

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $702.09 2019-2022
Astrazeneca Pharmaceuticals LP $568.00 2019-2022
Novo Nordisk INC $509.77 2019-2022
Dexcom, INC. $363.33 2020-2022
Lilly USA, LLC $351.81 2019-2021
Abbvie INC. $342.21 2019-2022
Xeris Pharmaceuticals, INC. $211.19 2020-2022
Boehringer Ingelheim Pharmaceuticals, INC. $163.65 2019-2021
Insulet Corporation $74.14 2019
Abbott Laboratories $45.18 2019-2020
Radius Health, INC. $43.16 2020-2021
Merck Sharp & Dohme LLC $42.88 2019-2020
Amgen INC. $42.16 2019-2020
Lifescan, INC. $36.65 2020
Ascensia Diabetes Care US INC. $35.89 2020-2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Tandem Diabetes Care, INC. $25.39 2019-2020
Antares Pharma, INC. $17.42 2022
Amarin Pharma, INC. $16.40 2021
Zealand Pharma US, INC. $14.32 2021
Companion Medical, INC. $12.68 2019
Janssen Pharmaceuticals, INC $11.36 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Bradford

$3,629.68

in general payments reported 2019-2025

Years
2019-2022
Top company
Sanofi-Aventis U.S. LLC

https://glasscript.com/doctor/342956/mark-bradford

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.